Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC

NCT05267262 is registered in ClinicalTrials.gov with River 3 Renal Corp. as lead sponsor.

NCT NCT05267262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC
Lead sponsor
River 3 Renal Corp.
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2022
Completion date
August 19, 2025
Enrollment
43 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome, focal segmental glomerulosclerosis